Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Overview
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Companies Involved in Therapeutics Development
Amgen Inc
Avacta Life Sciences Ltd
Celgene Corp
F. Hoffmann-La Roche Ltd
Numab Innovation AG
Provention Bio Inc
SYNIMMUNE GmbH
Tizia Life Sciences Plc
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Drug Profiles
AMG-330 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVA-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclol Antibodies to Target CD3, CD16 and HBsAg for HBV Infection and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclol Antibody to Target CD3E and PSMA for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
blitumomab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EM-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
foralumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to target CD3E and Cells Expressing NKG2D for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
otelixizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pasotuxizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-7082859 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TACSYN - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teplizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Dormant Products
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Product Development Milestones
Featured News & Press Releases
Apr 09, 2019: Provention Bio Initiates Phase 3 PROTECT clinical trial with PRV-031 (Teplizumab) in patients with recent onset Type 1 Diabetes
Mar 20, 2019: Tizia submits IND application for oral formulation of Foralumab for treatment of SH
Mar 06, 2019: Blitumomab for acute lymphoblastic leukaemia for people with minimal residual disease activity in remission
Jan 23, 2019: Amgen’s Blincyto gets expanded indication for B-cell ALL in Europe
Dec 03, 2018: Amgen announces first-in-human data evaluating investigatiol novel BiTE Immunotherapy AMG 330 At ASH 2018
Nov 28, 2018: Tizia announces initiation of phase 1 clinical trial with sal administration of Foralumab, a fully human anti-cluster definition 3 monoclol antibody (anti-CD3 mAb), in healthy volunteers
Nov 27, 2018: BLINCYTO for drip infusion 35 ?g launched in Japan for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia
Nov 16, 2018: Amgen receives CHMP positive opinion to expand use Of BLINCYTO (Blitumomab) in patients with minimal residual disease-positive B-Cell precursor Acute Lymphoblastic Leukemia
Nov 01, 2018: Roche presents early data for novel T-cell engaging bispecific antibody CD20-TCB at the American Society of Hematology 2018 Annual Meeting
Nov 01, 2018: Amgen to present new data on Blitumomab at ASH 2018
Nov 01, 2018: Amgen to present new data on its acute myeloid leukemia drug candidate AMG 330 at ASH 2018
Sep 24, 2018: U.S. Food and Drug Administration approves application for Investigatiol New Drug; Phase I clinical study set to commence enrolment in late 2018
Sep 24, 2018: BLINCYTO (blitumomab) approved in japan for the treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Aug 29, 2018: European Commission approves BLINCYTO (blitumomab) for use in pediatric patients with philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia
Aug 16, 2018: Tizia Life Sciences: filing of investigatiol new drug application
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019


List of Tables


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Amgen Inc, H1 2019
Pipeline by Avacta Life Sciences Ltd, H1 2019
Pipeline by Celgene Corp, H1 2019
Pipeline by F. Hoffmann-La Roche Ltd, H1 2019
Pipeline by Numab Innovation AG, H1 2019
Pipeline by Provention Bio Inc, H1 2019
Pipeline by SYNIMMUNE GmbH, H1 2019
Pipeline by Tiziana Life Sciences Plc, H1 2019
Dormant Projects, H1 2019